Biopharmaceutical company ImaRx Therapeutics of Tucson, AZ, reported revenue gains for the first quarter of 2008.
For the period (end-March 31), revenue increased to $1.9 million, up 63% from $1.2 million reported in the same period of 2007. ImaRx attributed the revenue growth to sales of urokinase, its therapy for treating acute massive pulmonary embolism.
The company's net loss for the period was $2.5 million, compared with $2.4 million in the first quarter of 2007. The increase was primarily a result of increased selling, general, and administrative expenses offset partially by increased sales of urokinase, which ImaRx is rebranding under the name Kinlytic, according to the company.
Related Reading
ImaRx posts Q2 revenue growth, lower net loss, August 31, 2007
ImaRx wins NIH study grant, August 23, 2007
ImaRx prices IPO, shares edge lower, July 27, 2007
Bracco, ImaRx sign licensing pact, July 4, 2007
ImaRx files S-1 for IPO, May 5, 2007
Unger steps down at ImaRx, October 24, 2006
Copyright © 2007 AuntMinnie.com
